Asitri Dashboard Search Clinical Trials
The U.S. National Library of Medicine provides a database of clinical trials worldwide. Use the fields below to search the database. Expand your results and select terms or phrases and right-click to search using Google, MalaCards, MedlinePlus, PubMed, or Wikipedia.
Saved Searches
Choose Search
Basic Search
Clinical Trials Search Results
Search History:
Count: 75
Selected: 0
| NCT ID | Title | ||
|---|---|---|---|
| NCT04922593 | Relative Bioavailability of LY03010 Compared to Listed Drug | ||
| NCT02988024 | Pilot BA Study of New LY03005 vs Pristiq | ||
| NCT05853341 | Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (13.3mg/24h) | ||
| NCT06098599 | Comparing the Pharmacokinetic Profile of LY01612 and CAELYX® in Chinese Subjects With Advanced Breast Cancer | ||
| NCT04571164 | A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD | ||
| NCT04045678 | A Multiple Ascending Dose Study With LY03003 in Patients With Early-stage Parkinson's Disease | ||
| NCT05862974 | A Dose-escalation Study of LPM3480392 in Chinese Healthy Subjects | ||
| NCT04638491 | Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients | ||
| NCT07516899 | Mass Balance Study of [14C] LPM3770164 in Healthy Participants | ||
| NCT02186769 | An Randomized Open-Label PK Study of LY03004 Compared to Risperdal® Consta® in Stable Patients With Schizophrenia or Schizoaffective Disorder | ||
| NCT06793995 | Effect of Food and Age on the Pharmacokinetics of LY03017 | ||
| NCT07371065 | To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics and Food Effects of LY03021 in Healthy Chinese Subjects | ||
| NCT04563936 | Efficacy and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | ||
| NCT04384666 | A Randomized, Open-Label, Crossover Study to Evaluate the Pharmacokinetic Profiles of Rotigotine After a Single Dose of LY03003 (28 mg) Versus After a Week of Daily NEUPRO® Transdermal Patch (4 mg Every 24 Hours) in Healthy Volunteers | ||
| NCT07396870 | A Phase 2 Study to Evaluate the Efficacy and Safety of LY03020 in Acutely Psychotic Participants With Schizophrenia | ||
| NCT06980207 | A Phase 1, MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of LY03017 | ||
| NCT04629404 | A Clinical Trial to Evaluate the Pharmacodynamics/Pharmacokinetics and Safety of LY03003 in Early PD Patients | ||
| NCT04044547 | A Study of LY03003 in Patients With Early-stage Parkinson's Disease | ||
| NCT06128837 | Study of LY01610 in Patients With Recurrent Small Cell Lung Cancer | ||
| NCT06216054 | Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects | ||
| NCT06426485 | To Evaluate the Long-term Efficacy and Safety of Toludevenlafaxine Hydrochloride Sustained-release Tablets | ||
| NCT06247410 | Clinical Trial to Investigate Patch Adhesion of Rotigotine Containing Patches in Patients With Parkinson's Disease | ||
| NCT02091388 | Bioavailability of LY03004 and Risperdal® Consta® | ||
| NCT04853407 | A Study to Evaluate the Efficacy and Safety of Ansofaxine Hydrochloride Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) | ||
| NCT05060406 | A Study to Evaluate the Efficacy and Safety of LY06006 in Postmenopausal Women With Osteoporosis at High Risk for Fracture | ||
| NCT06496048 | Lurbinectedin or in Combination with Irinotecan Versus Topotecan in Patients with Relapsed SCLC | ||
| NCT04198636 | A Study to Evaluate LY01011 and Xgeva® in Healthy Adults | ||
| NCT04973735 | A Phase I Study of LY-CovMab Injection in Chinese Healthy Subjects | ||
| NCT04630860 | A Study to Evaluate the Pharmacokinetics and Safety of LY03003 in Patients With Advanced-stage PD | ||
| NCT04593511 | to Evaluate the Safety, Tolerability and Pharmacokinetics of Four Formulations of LY03009 in Healthy Volunteers | ||
| NCT06731868 | Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia | ||
| NCT06388551 | A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 | ||
| NCT07391566 | LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation | ||
| NCT07292233 | A Food Effect Study of LY03020 in Healthy Subjects | ||
| NCT04572685 | Evaluate the PK of LY03010 Process 1 and Process 2 Drug Product vs INVEGA SUSTENNA After Intramuscular Injection in Schizophrenia Patients | ||
| NCT04381910 | Irinotecan Hydrochloride Liposome Injection (LY01610) For Small Cell Lung Cancer | ||
| NCT04627155 | A Study to Evaluate the Human Tolerance and Pharmacokinetics of LY03003 | ||
| NCT05857449 | An Exploratory Study of LPM3480392 at Different Infusion Rates in Chinese Healthy Subjects | ||
| NCT03844438 | A Study Evaluating the Safety, Tolerability of LPM3480226 Tablets in Patients With Advanced Solid Tumors | ||
| NCT03785652 | Dose-Finding Clinical Trial to Evaluate the Efficacy and Safety of LY03005 Extended-release Tablets in the Treatment of Major Depressive Disorder (MDD) | ||
| NCT02055300 | Safety, Tolerability and Pharmacokinetics Study of LY03005 | ||
| NCT04859569 | Efficacy and Safety of LY01011 and Xgeva® in Patients With Bone Metastases From Solid Tumors | ||
| NCT05140512 | Pharmacokinetics, Pharmacodynamics and Safety of LY01005 in Patients With Prostate Cancer Compared to ZOLADEX® | ||
| NCT05321602 | Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder | ||
| NCT03357796 | Relative Bioavailability (RBA) Study of LY03005 vs Pristiq® | ||
| NCT05238701 | A Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetic of LPM3770164 in Healthy Subjects | ||
| NCT03589066 | Pharmacokinetic Study of LY03003 in Patients With Parkinson's Disease | ||
| NCT06556966 | A Study Assessing the Safety and Tolerability of LY03020 in Chinese Healthy Subjects | ||
| NCT05856630 | Pharmacokinetics Pharmacodynamics and Safety of LY01022 in Patients With Prostate Cancer Compared With Zoladex® 10.8mg | ||
| NCT07236476 | Identify Effective Doses of LY01021 in Controlled Ovarian Hyperstimulation (COH) for Female Subjects Undergoing Assisted Reproductive Technology (ART) |
